Literature DB >> 10580514

Alcohol and molecular regulation of protein glycosylation and function.

M R Lakshman1, M N Rao, P Marmillot.   

Abstract

Chronic alcohol exposure leads to the appearance of carbohydrate-deficient transferrin (CDT), a N-glycosylated protein and sialic acid-deficient apolipoprotein E (apoE), an O-glycosylated protein. We show that chronic ethanol treatment destabilizes sialyltransferase (ST) mRNA resulting in a concomitant decreased steady-state level of ST mRNA. As a result, alcohol markedly decreases the hepatic synthetic rate of ST. This leads to impaired sialylation of transferrin and apoE. Consequently, apoE content in plasma high-density lipoproteins (HDL) is decreased. ApoE plays a significant role in the delivery of HDL cholesterol to the liver via apo B/E receptor, a process called reverse cholesterol transport (RCT). Desialylation of apoE results in its decreased association with HDL. Thus, the dissociation constant of HDL for binding to sialo-apoE is 90 +/- 35 nM, whereas that for desialo-apoE is 1010 +/- 250 nM. More importantly, the uptake of labeled cholesterol by human HepG2 cells is decreased by 30-40% from reconstituted HDL particles (rHDL)-containing desialo-apoE compared to rHDL with sialo-apoE. We conclude that chronic alcohol exposure down-regulates the expression of sialyltransferase genes resulting in impaired sialylation of apoE. This leads to its decreased binding to plasma HDL and thereby, impairs the RCT function of HDL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580514     DOI: 10.1016/s0741-8329(99)00041-5

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  1 in total

1.  Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.

Authors:  Martin A Javors; Chamindi Seneviratne; John D Roache; Nassima Ait-Daoud; Susan E Bergeson; M Consuelo Walss-Bass; Fatema Z Akhtar; Bankole A Johnson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-11-04       Impact factor: 5.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.